⚠️ No article content returned.
AstraZeneca PLC (AZN)
- Written by: Madison Wilson
Latest Company News
Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer.
Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer.
AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.
AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options.
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials.
AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion.
